摘要
目的评价莫西沙星序贯疗法治疗泌尿系感染的疗效及安全性。方法120例泌尿系感染患者随机分为2组,序贯组(60例)静脉点滴莫西沙星400mg,1次/d,5～7d后,予口服莫西沙星400mg,1次/d,序贯治疗,总疗程14d。对照组(60例)静脉点滴头孢哌酮/舒巴坦注射液2.0g,2次/d,疗程14d。结果治疗结束后第1天序贯组、对照组的临床痊愈率分别为80.0%、85.0%,临床有效率分别为91.7%、93.3%,细菌学有效率均为100%。治疗结束后第7天序贯组、对照组的临床痊愈率分别为83.5%、83.3%,临床有效率分别为93.2%、91.7%,细菌学有效率均为100%。两组临床痊愈率、有效率及细菌学疗效差异无统计学意义。莫西沙星序贯治疗组不良反应轻微,与对照组比较差异无统计学意义。结论莫西沙星序贯疗法治疗泌尿系感染,疗效确切、安全性好、经济、方便,有较高的临床应用价值。
Objective To evaluate the efficacy and safety of sequential moxifloxacin therapy in treatment of acute urinary tract infection. Methods 120 patients with acute urinary tract infection were randomly enrolled into 2 groups ：moxifloxacin injection foUowed by tablet（ sequential group）and cefoperazone/sulbactam injection group （control group）. In sequential group, moxifloxacin was given by intravenous infusion 400 mg, once daily for 5 - 7 days, followed by oral administration at the same dose,totally for 14 d. Cefoperazone/sulbactam Was given by intravenous infusion 2.0 g twice daily for 14 days in control group. Results The clinical cure rate in two groups were 80. 0% ,85.0% at the 1 st day after finishing the therapy,the clinical effective rates were 91.7% ,93. 3% ,the bacterial eradication rate were 100%, 100%. The clinical cure rate in two groups were 83.5%, 83.3% at the 7 th day after finishing the therapy ,the clinical effective rates were 93, 2% ,91.7% ,the bacterial eradication rate were 100% ,100%. There was no significant difference（P〉0. 05）between the two groups. In the clinical trial,there was no severe adverse effect occurred. The incidences of adverse effects have no statistic significance between 2 groups. Conclusion The sequential tberapy of moxifloxacin is safe,effective,economic and convenient for the treatment of acute urinary tract infection.
出处
《实用药物与临床》
CAS
2009年第1期15-17,共3页
Practical Pharmacy and Clinical Remedies
关键词
莫西沙星
序贯疗法
泌尿系感染
Moxifloxacin
Sequential therapy
Urinary tract infection
